(Toronto, Ontario) – Helix BioPharma Corp. (“Helix” or the “Company”) (TSX, FSE: “HBP”), a clinical stage, immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces today it has signed an exclusive out-license agreement with Xisle Pharma Ventures Trust (“Xisle”) for the Company’s late-stage, Biphasix™ technology platform, including the lead product candidate, interferon alpha. Xisle will be responsible for the continued clinical development and subsequent commercialization of the product for the treatment of HPV-induced, lowgrade, cervical intraepithelial lesions. As part of its asset development strategy, Xisle has initiated collaboration with senior pharmaceutical executives at Altum Pharmaceuticals Inc., who possess extensive regulatory, clinical, and product development expertise.
- 0 Comments
- FY2017